Biocardia, INC

BioCardia, Inc. outlines its business strategy, prioritizing the submission of CardiAMP Cell Therapy for approval in Japan and advancing its US clinical trials, alongside exploring strategic partnerships for its delivery platforms.

BioCardia, Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement following a successful capital raise.

BioCardia announced a $4.4 million financing, selling shares at an average price of $1.279, to extend its cash runway into early 2027 and beyond potential Japan PMDA submission.

BioCardia announced that the FDA confirmed its ongoing CardiAMP Heart Failure II trial may support Premarket Approval for its cell therapy system.

BioCardia received a positive Consultation Record from Japan's PMDA, clearing a path for regulatory submission of its CardiAMP cell therapy in Q4 2026.

BioCardia's CardiAMP CMI trial preliminary results show durable improvements in exercise tolerance and reduced angina in patients with chronic myocardial ischemia.

BioCardia, Inc. reported its first quarter 2026 financial results, highlighting ongoing development of its cell therapies and progress with regulatory bodies, while facing significant cash burn and Nasdaq listing concerns.

BioCardia reports significant clinical trial advancements for its cell therapies and delivery systems, alongside ongoing capital raises and a going concern warning.

BioCardia, Inc. reports significant net losses and liquidity challenges, raising substantial doubt about its ability to continue operations beyond October 2025, alongside a Nasdaq non-compliance notice.

BioCardia, Inc. reported significant net losses and a critical cash shortage, raising substantial doubt about its ability to continue operations beyond October 2025, despite ongoing clinical trial progress.

BioCardia's Q1 2025 results reveal a net loss and raise concerns about the company's ability to continue as a going concern without additional funding.

BioCardia's Q3 2024 report highlights progress in clinical trials, a recent capital raise, and ongoing efforts to advance its cell therapy platforms.

BioCardia, a clinical-stage company, announces its FY 2024 results, highlighting progress in its CardiAMP cell therapy trials for heart failure and chronic myocardial ischemia, as well as its allogeneic MSC therapy platform.

BioCardia's 2023 10-K filing highlights ongoing clinical trials for its cell therapy platforms and its financial position as a clinical-stage company.

Peter Altman, President and CEO and a Director of BioCardia, Inc., purchased 5,000 shares of common stock on July 29, 2026 for $0.78 per share.

Peter Altman, President and CEO and a Director of BioCardia, Inc., purchased 500 shares of common stock on July 17, 2026 for $0.83 per share.

Peter Altman, President and CEO and a Director of BioCardia, Inc., purchased 4,300 shares of common stock on July 14, 2026.

BioCardia, Inc. President and CEO Peter Altman acquired a total of 7,500 shares of common stock across three transactions in early July 2026.

BioCardia, Inc. President and CEO Peter Altman reported a transaction involving the sale of 5,400 shares of common stock.

BioCardia, Inc. reports that Director Simon H. Stertzer acquired 8,000 stock options on July 6, 2026.

BioCardia, Inc. announced its 2025 Annual Meeting of Stockholders will address the election of three Class III directors, an extension and amendment of its 2016 Equity Incentive Plan, and the ratification of its independent auditor.

BioCardia is asking stockholders to approve a reverse stock split and other corporate governance matters at its upcoming annual meeting to maintain its Nasdaq listing and for other corporate purposes.

BioCardia, Inc. filed an amendment to its S-1 registration statement, primarily updating its engagement agreement with H.C. Wainwright & Co., LLC for capital raising services and delaying the effective date.

BioCardia, Inc. is offering up to 2.8 million shares and warrants to raise $5.3 million, aiming to fund clinical trials and operations while facing a Nasdaq compliance deadline.

BioCardia, Inc. has filed a registration statement to offer an additional $1.2 million in common stock, pre-funded warrants, and accompanying common warrants.

BioCardia, Inc. announces a best efforts offering to raise up to $5.3 million through the sale of common stock, pre-funded warrants, and common warrants to fund working capital and general corporate purposes.

BioCardia, Inc. files for a best efforts public offering of common stock, pre-funded warrants, and common warrants to raise capital for general corporate purposes.

Andrew Scott Blank, Chairman of BioCardia, Inc.'s Board of Directors, has increased his beneficial ownership in the company to 5.5% following a recent private placement and other share acquisitions.

Joseph P. Daly has filed an amended Schedule 13D indicating he no longer beneficially owns more than 5% of BioCardia, Inc.'s common stock as of May 13, 2025.

Intracoastal Capital, along with Mitchell P. Kopin and Daniel B. Asher, reported a 4.99% passive beneficial ownership stake in BioCardia, Inc. common stock.

Lincoln Alternative Strategies LLC has reported a beneficial ownership of 7.54% in BioCardia, Inc., holding 800,000 shares of common stock.

Thomas A. Satterfield, Jr. has increased his beneficial ownership in BioCardia, Inc. to 9.9% of the common stock, including shares and exercisable warrants.

Thomas A. Satterfield, Jr. has filed an amended Schedule 13G, disclosing a beneficial ownership of 8.2% of BioCardia, Inc.'s common stock as of December 31, 2024.